1. Lack of Significance of the BRCA2 Promoter Methylation Status in Different Genotypes of the MTHFR a1298c Polymorphism in Ovarian Cancer Cases in Iran
- Author
-
Mehdi Nikbakht Dastjerdi, Hamidreza Gaafarineveh, Zahra Taghipour, Zahra Babazadeh, Hajar Dahim, Mohammadreza Slahshoor, M M Taghavi, and Ahmad Shabanizadeh Darehdori
- Subjects
Cancer Research ,Genotype ,endocrine system diseases ,Epidemiology ,Iran ,Biology ,Polymerase Chain Reaction ,chemistry.chemical_compound ,Promoter methylation ,medicine ,Humans ,Gene silencing ,Promoter Regions, Genetic ,Gene ,Methylenetetrahydrofolate Reductase (NADPH2) ,Neoplasm Staging ,BRCA2 Protein ,Ovarian Neoplasms ,Genetics ,Polymorphism, Genetic ,Public Health, Environmental and Occupational Health ,Methylation ,DNA Methylation ,Middle Aged ,Prognosis ,medicine.disease ,Molecular biology ,Oncology ,chemistry ,Case-Control Studies ,Methylenetetrahydrofolate reductase ,biology.protein ,Female ,Ovarian cancer ,Polymorphism, Restriction Fragment Length ,DNA - Abstract
Objective: Promoter methylation, which can be regulated by MTHFR activity, is associated with silencing of genes. In this study we evaluated the methylation status (type) of the BRCA2 promoter in ovarian cancer patients carrying different genotypes of the MTHFR gene (A or C polymorphisms at position 1298). Methods: The methylation type of the BRCA2 promoter was evaluated using bisulfate-modified DNA in methylationspecific PCR and the MTHFRa1278c polymorphism was assessed by PCR-RFLP. Results: Analysis of the BRCA2 promoter methylation type of cases showed that 7 out of 60 cases (11.7%) were methylated while the remaining 53 (88.3%) were unmethylated. In methylated cases, one out of the 7 cases had a CC genotype and the remaining 6 methylated cases had an AC genotype. The AA genotype was absent. In unmethylated cases, 34, 18, and one out of these had AC, AA and CC genotype, respectively. Conclusion: There was no significant relationship between the methylation types of the BRCA2 promoter in different genotypes of MTHFRa1298c polymorphism in ovarian cancer; p=0.255. There was no significant relation between the methylation types of the BRCA2 promoter in different genotypes of the MTHFRa1298c polymorphism in ovarian cancer.
- Published
- 2012